Clark exits Merck Dec. 1, passing chairman title to CEO

Merck ($MRK) Chairman Richard Clark (photo) will retire Dec. 1, leaving Kenneth Frazier (photo) with the dual role of chairman and CEO. Frazier took the operational reins at Merck in January after the company's mandatory retirement age forced Clark to step down. Report | Item

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.